The World Health Organization has announced its recommendations for the 2026–2027 Northern Hemisphere influenza vaccine composition, highlighting two key developments: the continued spread of A (H3N2) subclade K and the growing circulation of new B/Victoria lineage strains. In response, Sino Biological has launched a comprehensive panel of antigens for these strains to accelerate influenza vaccine development.
Since its identification in August 2025, H3N2 subclade K has become the dominant influenza A strain worldwide. Defined by the T135K and S144N mutations, this strain exhibits enhanced immune escape, prompting WHO's selection of A/Darwin/1454/2025 as the new H3N2 reference viruses. The H1N1 component has been updated to A/Missouri/11/2025.
Influenza B activity is rising sharply, with the proportion of B/Victoria lineage viruses increasing from 6% to over 20% in regions such as Hong Kong and the U.S. These trends led WHO to recommend B/Tokyo/EIS13-175/2025 and B/Pennsylvania/14/2025 strains for the upcoming season.
Sino Biological's portfolio includes recombinant antigens spanning key viral antigens including Hemagglutinin, Neuraminidase, and Nucleoprotein. For H1N1, A/Missouri/11/2025 HA Trimer, NA, and NP antigens are available now. For H3N2 subclade K, recombinant HA, NA, and NP aligned with A/Darwin/1454/2025 are also available. Influenza B reagents for B/Tokyo/EIS13-175/2025 and B/Pennsylvania/14/2025 are in development. The company provides stable HA trimers that maintain native conformation for accurate immune characterization.
Dr. Rob Burgess, Chief Business Officer at Sino Biological US, stated that the company's mission is to provide the scientific community with high-quality tools rapidly when infectious disease evolution threatens global health preparedness. More information about the company can be found at https://www.sinobiological.com. The original release is available on https://www.newmediawire.com.
This development matters for Texas's biotech and pharmaceutical sectors, as timely access to accurate antigens is critical for vaccine manufacturers to meet production timelines ahead of the flu season. The economic impact extends to healthcare systems and employers who face costs from influenza-related absenteeism and hospitalizations. For the global community, rapid response tools against evolving strains like H3N2 subclade K, which shows enhanced immune escape, are essential for maintaining vaccine efficacy and public health preparedness. Sino Biological's initiative supports the broader industry's ability to adapt to viral evolution, potentially reducing the burden of seasonal influenza in Texas and worldwide.
